Abeona Therapeutics Inc
Abeona Therapeutics IncProfile last edited on: 2/21/2020
4848 Lemmon AvenueDallas, TX 75219
|
Business Identifier: Gene therapies for rare genetic diseases: potential cures for Sanfilippo syndrome types A and B
Public Profile:
Formerly known as PlasmaTech Biopharmaceuticals Inc, Abeona Therapeutics was originally trading on AMEX. Following delisting, the firm moved to OTC. The firm then issued another IPO on NASDAQ in December 2015. With technologies licensed from the Universiies of Minnnesota, Nebraska and North Carolina, Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Lead programs are adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA) in collaboration with patient advocate groups, researchers, and clinicians. The company is also developing gene therapy for juvenile Batten disease (JBD); and for Fanconi anemia (FA) disorder using a CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, it is developing rare plasma protein therapies, including SDF AlphaT (alpha-1 protease inhibitor) for inherited COPD using its proprietary Salt Diafiltration (SDFT) ethanol-free process. The company is involved in marketing MuGard, a mucoadhesive oral wound rinse for mucositis, stomatitis, aphthous ulcers, and traumatic ulcers; and ProctiGard, a mucoadhesive oral wound rinse for the treatment of rectal mucositis and radiation proctitis.
Formerly known as PlasmaTech Biopharmaceuticals Inc, Abeona Therapeutics was originally trading on AMEX. Following delisting, the firm moved to OTC. The firm then issued another IPO on NASDAQ in December 2015. With technologies licensed from the Universiies of Minnnesota, Nebraska and North Carolina, Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Lead programs are adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA) in collaboration with patient advocate groups, researchers, and clinicians. The company is also developing gene therapy for juvenile Batten disease (JBD); and for Fanconi anemia (FA) disorder using a CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, it is developing rare plasma protein therapies, including SDF AlphaT (alpha-1 protease inhibitor) for inherited COPD using its proprietary Salt Diafiltration (SDFT) ethanol-free process. The company is involved in marketing MuGard, a mucoadhesive oral wound rinse for mucositis, stomatitis, aphthous ulcers, and traumatic ulcers; and ProctiGard, a mucoadhesive oral wound rinse for the treatment of rectal mucositis and radiation proctitis.
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Unlock access
To unlock access to all SBIR-STTR company Profiles, a FREE site registration is required. Click here to register or login if you already have an account
To unlock access to all SBIR-STTR company Profiles, a FREE site registration is required. Click here to register or login if you already have an account Smart Office Options
|
|
SBIR firms in the news
WikiProfile
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Processing...